Imagyn starts sales of Site Select

Article

Imagyn Medical Technologies of Newport Beach, CA, last month concluded U.S. beta trials for its Site Select breast biopsy device. The company began the trials at 21 sites in September and, with their completion, has begun to market the device. Site

Imagyn Medical Technologies of Newport Beach, CA, last month concluded U.S. beta trials for its Site Select breast biopsy device. The company began the trials at 21 sites in September and, with their completion, has begun to market the device. Site Select allows physicians to locate and extract a biopsy specimen in one step. When the device is used with a stereotactic table, biopsies can be done with local anesthesia on an outpatient basis.

Newsletter

Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.

Recent Videos
Reducing Mammography Workload by Nearly 40 Percent? What a New Hybrid AI Study Reveals
 What New Research Reveals About Portable Low-Field MRI and Patients with Suspected Alzheimer’s Disease
Diagnostic Imaging's Weekly Scan: August 11 — August 17 (Video Version)
© 2025 MJH Life Sciences

All rights reserved.